Welcome to our dedicated page for Scpharmaceutical news (Ticker: SCPH), a resource for investors and traders seeking the latest updates and insights on Scpharmaceutical stock.
scPharmaceuticals Inc. (formerly traded on Nasdaq under the symbol SCPH) generated a steady stream of company-specific news before and during its acquisition by MannKind Corporation. Public announcements and SEC filings show that scPharmaceuticals focused on cardiorenal healthcare, with news often centered on FUROSCIX, a subcutaneous furosemide injection indicated for the treatment of edema in adult patients with chronic heart failure or chronic kidney disease, including nephrotic syndrome.
News coverage for scPharmaceuticals has included product and clinical updates, such as FDA approval of an expanded FUROSCIX indication to include chronic kidney disease and the formal launch of FUROSCIX into that market. The company also reported progress on its SCP-111 furosemide formulation and related autoinjector program, including multiple Notices of Allowance from the U.S. Patent and Trademark Office for patents covering SCP-111 and plans for supplemental NDA submissions.
Financial and corporate updates have been another major theme. scPharmaceuticals regularly issued press releases on quarterly and annual financial results, highlighting net FUROSCIX revenues, dose volumes, prescriber adoption, and expansion into integrated delivery networks. Additional news detailed participation in investor conferences, financing arrangements, and credit facilities.
A key set of news items in 2025 described MannKind’s agreement to acquire scPharmaceuticals, the tender offer terms, and the strategic rationale around cardiorenal and cardiometabolic care. Subsequent releases and a Form 8-K dated October 7, 2025 confirmed completion of the tender offer and merger, after which scPharmaceuticals became a wholly owned subsidiary of MannKind and its shares were delisted from Nasdaq. This news page therefore serves as an archive of historical announcements, from product and regulatory milestones to the transaction that ended SCPH’s life as an independent public stock.
scPharmaceuticals Inc. (Nasdaq: SCPH) announced a conference call scheduled for March 22, 2023, at 4:30 p.m. ET to discuss its fourth quarter 2022 financial results and provide a business update. The call will be accessible via telephone and an audio webcast. The company focuses on developing innovative pharmaceuticals aimed at reducing healthcare costs and improving patient outcomes, specifically targeting outpatient care for acute conditions such as heart failure and infectious diseases.
scPharmaceuticals Inc. (Nasdaq: SCPH) announced that CEO John Tucker will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference on March 8 at 10:30 am ET in Boston. This event will highlight the company's focus on developing and commercializing products aimed at optimizing the delivery of infused therapies and improving patient care while reducing healthcare costs. Tucker will also meet with investors from March 6 to 8. A live webcast of the chat will be available on the company's website under the Investor Relations section.
scPharmaceuticals Inc. (Nasdaq: SCPH) has announced the commercial launch of FUROSCIX®, a proprietary formulation of furosemide for treating congestion in patients with NYHA Class II and III chronic heart failure. This product allows for outpatient management through an on-body infusor, delivering an 80-mg dose. The CEO, John Tucker, emphasized the potential for FUROSCIX to reduce hospital admissions and save healthcare costs. Safety information indicates contraindications and possible adverse reactions during therapy. An earnings call in March will provide further updates on this initiative and other developments.
On February 1, 2023, scPharmaceuticals (Nasdaq: SCPH) announced the granting of stock options to 38 new employees, totaling 142,500 shares. The options are part of the Inducement Plan, following Nasdaq Listing Rule 5635(c)(4), aimed at incentivizing talent acquisition. Each option has an exercise price of $6.84 and vests over four years, with 25% vesting after the first year and the remainder in monthly installments. The company focuses on developing solutions to improve healthcare outcomes and reduce costs, especially in outpatient care for heart failure and infectious diseases.
scPharmaceuticals Inc. (Nasdaq: SCPH) announced that John Tucker, its President & CEO, will present virtually at the SVB Securities Global Biopharma Conference on February 16, 2023, at 11:20 am ET. During this conference, Tucker will also engage in one-on-one meetings with investors. The company focuses on optimizing infused therapies and reducing healthcare costs, particularly through self-administrable treatments for heart failure and infectious diseases. Headquartered in Burlington, MA, scPharmaceuticals aims to enhance outpatient care while improving health outcomes.
scPharmaceuticals Inc. (Nasdaq: SCPH) plans to commercially launch FUROSCIX (furosemide injection) on February 20, 2023. This product is designed for the outpatient treatment of congestion due to fluid overload in patients with NYHA Class II and III chronic heart failure. The On-Body Infusor will deliver a single dose of 80 mg, and the medication is not for emergency situations. CEO John Tucker notes that Medicare and Medicaid beneficiaries will have access from day one, with discussions ongoing to expand reimbursement coverage. Management will provide detailed updates during the fourth quarter earnings call scheduled for March.
scPharmaceuticals Inc. has appointed Rachael Nokes as its new Chief Financial Officer, bringing over 20 years of leadership experience in life sciences finance.
Previously the Senior Vice President of Finance at the company, Nokes is expected to lead financial strategies as the firm prepares for the commercial launch of FUROSCIX®. This drug is aimed at treating fluid overload in chronic heart failure patients. Nokes's extensive background includes significant roles at BG Medicine Inc. and PriceWaterhouseCoopers, enhancing her capability in managing public-company finance functions.
scPharmaceuticals Inc. (Nasdaq: SCPH) announced that CEO John Tucker will participate in the 12th Annual LifeSci Partners Corporate Access Event on January 9-10, 2023, in San Francisco. The company focuses on developing products to optimize infused therapies, improve patient care, and reduce healthcare costs. Their key initiatives aim to facilitate outpatient treatment for acute conditions, particularly in heart failure and infectious diseases through subcutaneous self-administration of IV-strength therapies. More details regarding the event can be found on their website.
scPharmaceuticals Inc. (Nasdaq: SCPH) announced a public offering of 6,620,000 shares of common stock at $5.25 each, alongside a prefunded warrant for 2,905,000 additional shares at $5.249 each. The total gross proceeds are projected at approximately $50 million, prior to expenses. The offering is set to close on November 25, 2022, pending customary conditions. SVB Securities and Cowen are leading the offering. The securities are registered under a shelf registration statement filed with the SEC.
scPharmaceuticals Inc. (Nasdaq: SCPH) announced FDA marketing approval for FUROSCIX, a self-administered, subcutaneous diuretic for chronic heart failure treatments, marking a potential breakthrough in patient care. The company secured a $100 million debt financing agreement to aid commercialization efforts, with a planned launch in Q1 2023. Financially, third-quarter results showed a net loss of $10.2 million, while cash reserves decreased to $45.4 million. The adjusted net loss guidance for 2022 is now $38 to $41 million, a reduction from prior estimates.